1 day Ago By ABMN Staff
Virtu Financial LLC acquired a new position in shares of Skye Bioscience, Inc. ( NASDAQ:SKYE – Free Report ) in the fourth quarter, HoldingsChannel reports. The fund acquired 10,142 shares of the company’s stock, valued at approximately $29,000.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Sphera Funds Management LTD. grew its position in shares of Skye Bioscience by 20.
4% during the 3rd quarter. Sphera Funds Management LTD. now owns 1,563,522 shares of the company’s stock worth $6,113,000 after buying an additional 265,210 shares during the period.
Geode Capital Management LLC grew its holdings in Skye Bioscience by 4.2% during the third quarter. Geode Capital Management LLC now owns 385,793 shares of the company’s stock valued at $1,509,000 after purchasing an additional 15,614 shares during the period.
State Street Corp increased its stake in Skye Bioscience by 7.0% in the third quarter. State Street Corp now owns 354,205 shares of the company’s stock valued at $1,385,000 after purchasing an additional 23,201 shares in the last quarter.
Charles Schwab Investment Management Inc. raised its holdings in Skye Bioscience by 20.7% in the fourth quarter.
Charles Schwab Investment Management Inc. now owns 62,363 shares of the company’s stock worth $176,000 after purchasing an additional 10,707 shares during the period. Finally, Barclays PLC boosted its position in shares of Skye Bioscience by 36.
7% during the third quarter. Barclays PLC now owns 57,889 shares of the company’s stock worth $226,000 after purchasing an additional 15,551 shares in the last quarter. Institutional investors own 21.
09% of the company’s stock. Skye Bioscience Price Performance SKYE stock opened at $1.40 on Wednesday.
The business has a 50-day moving average of $2.36 and a 200-day moving average of $2.71.
Skye Bioscience, Inc. has a fifty-two week low of $1.37 and a fifty-two week high of $17.
65. The stock has a market capitalization of $43.37 million, a P/E ratio of -1.
94 and a beta of 1.71. Analysts Set New Price Targets Several analysts recently commented on the company.
Craig Hallum dropped their price objective on Skye Bioscience from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, March 21st.
William Blair reiterated an “outperform” rating on shares of Skye Bioscience in a report on Friday, March 21st. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Skye Bioscience currently has a consensus rating of “Buy” and a consensus price target of $18.
00. Get Our Latest Report on SKYE Skye Bioscience Profile ( Free Report ) Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension.
It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. Further Reading Want to see what other hedge funds are holding SKYE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Skye Bioscience, Inc.
( NASDAQ:SKYE – Free Report ). Receive News & Ratings for Skye Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Skye Bioscience and related companies with MarketBeat.com's FREE daily email newsletter .
.
_8.jpg?itok=wp-xhXRB)
